Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Changes in Physical Parameters from baseline to 8 weeks in the Placebo and in LI85008F supplemented group

From: Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study

Measure Study Period Placebo (x ± SE) P valuea LI85008F (x ± SE) P valuea P valueb
Body Wt. (Kg) Baseline 84.97 ± 2.80 < 0.001 86.16 ± 2.75 < 0.001 -
8 week 83.18 ± 2.82 81.40 ± 2.69
Change 1.79 ± 0.34 - 4.76 ± 0.51 - < 0.001
Body Mass Index (kg/m²) Baseline 33.00 ± 0.73 < 0.001 34.41 ± 0.74 < 0.001 -
8 week 32.30 ± 0.74 32.51 ± 0.75
Change 0.70 ± 0.13 - 1.90 ± 0.19 - < 0.001
Waist Circumference (cm) Baseline 108.59 ± 1.99 < 0.001 106.68 ± 1.67 < 0.001 -
8 week 97.35 ± 2.53 94.16 ± 2.17
Change 11.24 ± 1.95 - 12.52 ± 1.83 - 0.6384
Hip Circum (cm) Baseline 119.51 ± 1.50 < 0.001 117.99 ± 1.67 < 0.001 -
8 week 110.68 ± 1.85 108.07 ± 1.65
Change 8.83 ± 0.99 - 9.92 ± 1.34 - 0.0934
Waist-Hip Ratio (WHR) Baseline 0.91 ± 0.01 <0.05 0.91 ± 0.01 <0.05 -
8 week 0.88 ± 0.01 0.87 ± 0.02
Change 0.03 ± 0.01 - 0.04 ± 0.01 - >0.05
Systolic B.P. (mmHg) Baseline 120.40 ± 3.40 0.4341 123.33 ± 2.87 0.4094 -
8 week 118.00 ± 3.04 126.19 ± 2.80
Change 2.40 ± 2.93 - −2.86 ± 3.39 - 0.2618
Diastolic B.P. (mmHg) Baseline 76.20 ± 1.95 0.7388 80.00 ± 2.29 0.5614 -
8 week 75.50 ± 1.53 81.43 ± 2.10
Change 0.70 ± 2.02 - −1.43 ± 2.42 - 0.2146
Heart Rate (Beats/mim) Baseline 73.20 ± 0.62 0.5953 74.29 ± 0.92 0.6676 -
8 week 74.00 ± 1.34 74.95 ± 0.91
Change −0.80 ± 1.45 - −0.67 ± 1.53 - 0.4006
  1. a Difference within the group (baseline vs. final evaluation) using paired t-test.
  2. b Difference between changes (derived from baseline minus final evaluation) in placebo and LI85008F group using unpaired t-test.